HALIFAX, NS – STI Technologies Limited (STI) is pleased to announce the addition of Michel Lamontagne to its Board of Directors and Sylvain Baril as its Quebec-based Senior Manager of Business Development.

Sylvain joins the STI team with more than 15 years’ experience in various roles within the pharmaceutical and healthcare industry.  During his pharmaceutical career, Sylvain has been involved in major social and community investments creating amazing value for Quebec patients.                                      

Based in Verdun and Magog, Quebec, Michel brings a wealth of knowledge of the Quebecois healthcare landscape along with many years’ experience in federal, provincial, municipal and in private sector corporate governance.

A tax lawyer by training, Michel has spent much of his career in the pharmaceutical and healthcare sector. Michel was previously a member of the executive committee of Bristol-Myers Squibb Pharmaceutical Group Canada, former Chair of the RAMQ and former Vice-Chair of the board, Chair of the Vigilance Committee and member of the Audit Committee of the Douglas Mental Health Institute. Michel continues to serve as Chair of Magog Technopole.

The additions of Michel and Sylvain support STI’s continued commitment to the Quebec healthcare system.

“With these appointments to the STI team we will continue to focus our attention on bringing our programs and services to Quebec-based patients,” says Tim Gillis, CEO. “We are committed to addressing the unique needs of the Quebec market through strong, positive relationships.”

STI Technologies Limited is the largest intelligent reimbursement solutions providers to the Canadian healthcare industry, implementing innovative programs on behalf of health care providers of products and services, in the context of responsible patient choice. Using an advanced patient-centric technology platform, all of STI’s programs support greater access and choice to medications and healthcare products to improve patient outcomes.

# # #

For more information on STI Technologies Limited, please visit www.smartsti.com or contact:

Catherine St-Jacques, B.Pharm, MBA
Senior Consultant, Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
(514) 843-2346

 

Companies will combine digital communications and card based validated solutions, to provide integrated approach to increasing patient medication adherence

Toronto, ON – MEMOTEXT Corp. announces today the formation of a strategic alliance with STI Technologies Limited to provide state-of-the art digital communications platform and smart-card technology, to improve patient compliance with medications.

The two Canadian companies are collaborating to integrate their technologies to solve a very costly healthcare problem. Despite operating in different spaces of the healthcare industry, both companies have evidence-based methodologies and validated solutions that complement each other. MEMOTEXT’s JAMA published clinically validated digital adherence solutions have been shown to increase patient adherence by 31.4%. While STI’s recent “STI Reimbursement Programs Correlate with Higher Medication Possession Ratios” discussion paper, demonstrates a 30% relative improvement in medication possession ratio (MPR) over a 12-month period for patients benefiting from a reimbursement solution program. By combining MEMOTEXT’s experience in digital health with STI Technologies’ reimbursement solution technology, the two offer a supercharged adherence program that achieves far greater increases in adherence and MPR than either company could accomplish on its own.

This new partnership will integrate MEMOTEXT’s communications platform and personalized behaviour change messaging, with STI Technologies’ personalized reimbursement solutions. The result is an intervention with far greater increases in adherence and MPR. “We are excited that the findings validate what we’ve been hearing from patients and healthcare professionals for years. Patients highly value these reimbursement programs” says Tim Gillis CEO of STI Technologies “Both STI and MEMOTEXT have a focus on personalized healthcare and a proven track record in improving patient’s adherence and their MPR. It’s exciting to see what we can accomplish in the coming years. By combining our technology, methodologies and offerings into integrated solutions, our partnership will revolutionize patient adherence programs in Canada.”

The alliance brings together STI’s reimbursement support programs, which helps patients with their prescriptions and other healthcare expenses, with MEMOTEXT’s proprietary clinical algorithms and evidence based personalized digital communications. The resulting platform integrates financial assistance for health related services and products with personalized adherence reminders to create a system that delivers validated outcomes, real-time, data-driven, support and behaviour change. The end result is a holistic patient adherence program unlike any other offered in Canada.

“With STI’s expertise in helping patients manage their healthcare expenses and our experience in improving adherence, we complement each other extremely well” said Amos Adler, M.Sc., Founder and President of MEMOTEXT “It’s great that two Canadian digital health companies are collaborating to provide integrated, more affordable, and more effective health interventions. It is a truly exciting time for both of our companies.”

About MEMOTEXT

MEMOTEXT improves outcomes for patients and the bottom line for healthcare stakeholders by ensuring patients adhere to their treatment. With a proprietary, evidence-based self-learning algorithm and communications platform, MEMOTEXT integrates behavior change into the everyday lives of patients with personalized, secure, interactive voice, text, and mobile communications. Visit www.memotext.com

ABOUT STI

STI Technologies Limited is the largest intelligent reimbursement solutions provider to the Canadian healthcare industry, implementing innovative programs on behalf of major pharmaceutical companies. STI's flagship solution, innoviCares, is a free program that provides additional financial coverage for nearly 100 brand-name medications and other healthcare products, providing patients with greater choice and access.

Visit www.smartsti.com 

Dave Morton joins the STI Technologies Limited team with a rich history in pharmaceutical marketing, leadership and agency experience. Known amongst his peers as a seasoned and innovative marketer, Dave prides himself on a customer-centric, strategic leadership and management approach. 

Prior to joining STI in early 2015, Dave spent 14 years in various leadership roles, including EVP managing director at JSA Canada - one of the country’s largest healthcare marketing and communications companies. During his time with JSA, Dave was in charge of many market-leading brands, developing a number of award-winning healthcare professional and direct-to-consumer campaigns at the national level.

“We are excited to welcome Dave to our team and look forward to benefiting from his extensive knowledge and experience," says Tim Gillis, CEO. "Dave's background in pharmaceutical marketing and sales combined with his commitment to patient-centric care aligns with our strategic priorities, particularly around specialty, adherence and creating effective programs for our clients across the product lifecycle." 

Dave previously spent 10 years with Rhone Poulenc Rorer (now Sanofi Canada) in various progressive sales and marketing positions. 

Residing in Montreal for the last 17 years, Dave and his family are excited to return home to their Atlantic Canadian roots.

Halifax, N.S. (March 12, 2015) —STI Technologies Limited has been named one of Canada’s Best Managed Companies in 2014. Sponsored by Deloitte, CIBC, National Post, Queen’s School of Business and MacKay CEO Forums, this award recognizes Canadian-owned and -managed companies with revenues of over $10 million for sustained growth, financial performance and management practices.

“We’re thrilled and extremely proud to receive this national award of business excellence,” says STI Technologies CEO Tim Gillis. “Our people are focused on innovation and the delivery of programs to millions of Canadian patients. STI has seen consistent growth over the past few years and has expanded the company with diverse and talented people to meet the needs and expectations of our clients. Every member of our team should take ownership of this award.”

STI Technologies is a Halifax-based health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health-care products. Led by former CEO Steve Nicolle until the end of 2014, STI has seen sustained growth supporting the health-care system by delivering reimbursement, patient-engagement and patient-management solutions that improve health outcomes through partnerships with Canada’s top pharmaceutical companies.

By making its user-friendly solutions available online and through health-care providers across the country, STI is the leader in its industry, with millions of patients benefiting from its programs. Its free innoviCares patient-benefit plan is the ninth-largest private plan in Canada, covering nearly 100 medications and products from 20 drug manufacturers; to date, it has helped about 800,000 Canadians.

STI’s business model has adapted and evolved over the last 12 years as the company has gained a better understanding of the market challenges faced by its clients. “As we develop innovative products to meet our clients’ needs, we recognize that this sustained success will lead to improved patient engagement, adherence and continuity of care—and, ultimately, to better health outcomes for many Canadians,” says Gillis.

About Canada’s Best Managed Companies

Every year since the launch of the program in 1993, hundreds of entrepreneurial companies have competed for this designation in a rigorous and independent process that evaluates their management skills and practices. The awards are granted on four levels: Best Managed winner; Requalified member; Gold Standard winner; and Platinum Club member. For more information, visit bestmanagedcompanies.ca.

For more information, please contact:

Erin Solomon, marketing associate
STI Technologies Limited, smartsti.com
(902) 442-2071
, (902) 877-1849
, This email address is being protected from spambots. You need JavaScript enabled to view it.

 

innovicares-bday-graphicsHalifax, N.S. (Jan. 26, 2014) — STI Technologies Limited is marking two years of helping Canadian patients have greater access to medications through its free innoviCares patient-benefit plan. The innoviCares plan includes many types of benefits, such as allowing patients to receive brand-name medications and health-care products at an equal or similar price to the generic alternatives.

When the plan launched, 12 medications were covered; today innoviCares is the ninth-largest private plan in Canada, and covers nearly 100 medications and products from 20 drug manufacturers. There are no monthly fees, and the innoviCares card has been accepted at over 98 per cent of Canadian pharmacies.

"Our innoviCares plan continues to grow," says Tim Gillis, chief executive officer at STI. "We're adding more tools, resources and benefits for patients to help patients manage their medications."

To date, the innoviCares card has helped nearly 800,000 Canadians, with over 50,000 benefitting from the plan each week. In addition to covering such well-known medications as Crestor, Ezetrol, Imovane, and Cipralex, innoviCares also offers free benefits towards such products as diabetes blood-glucose meters and test strips. "The innoviCares plan improves patients' medication choices," says Gillis. "The stress that people are under to be able to afford certain medications is huge. We're here to help them with that."

Partnering pharmaceutical companies believe that greater access and patient choice to the most effective medications helps lead to better health outcomes. "With this in mind, we've added 14 Sanofi products to the innoviCares plan to ensure patient access to brand-name medications prescribed by their physician", says Tracey Ramsay, Sanofi Canada's Vice President of Hospital, Specialty and Consumer Health.

STI Technologies Limited is the largest intelligent reimbursement solutions provider to the Canadian healthcare industry, implementing innovative programs on behalf of major pharmaceutical companies. Using their advanced patient-centric technology platform, all of the Halifax-based company's programs, support greater access and choice to medications and health-care products to improve patient outcomes. Visit smartsti.com to learn more.

For more information, please contact:
Erin Solomon, marketing associate
STI Technologies Limited
(902) 442-2071
 and (902) 877-1849
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Page 1 of 8

What's Happening

nexium.jpg